Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Makes me wonder how the shareholder meeting will go, will we walk up to the door and see a note attached that reads:
My fellow shareholders I am sorry but I lost my key in the snow, please meet me at the Dunkin Donuts in Beverly.
(There are 5 in Beverly but he doesn't say which one he could be at:)
Honestly I think it will all be good after Menon present B updates!
This is quite bizarre no matter how you spin it.
He had one job and that was to attend an important meeting that he never got to because he supposedly had some secret meeting of his own going on.
I can picture the stock taking a beating on this one, better yet a new seeking alpha piece digesting the latest events and spewing unthinkable nonsense to the masses.
GLTA
Until it is discredited I will stick with Leo's story.
If BARDA, NIH, FDA, grant agencies, pharma and academia were present I would think it would be held in private.
At 15:10 there were 4 roundtables taking place at the same time, I would assume they were not held next to each other but met in private.
RoundtablesRoundtable 1: Barriers to antibiotic discoveryMs Carolyn Shore, Officer of Antibiotic Resistance Project, The Pew Charitable TrustsRoundtable 2: Monoclonal antibodies as an antibiotic alternativeJose Senna, Researcher, Bio-Manguinhos/FiocruzRoundtable 3: Fully synthetic development approaches for reducing off-target effectsRoger Beuerman, Chief Scientific Officer, SinSa Labs Inc.Roundtable 4: Companion diagnostics: Facilitating collaboration between pharma and diagnosticsSamuel Bozzette, Vice President of Medical Affairs, Biomerieux Inc
There's more than just health meetings in San Francisco for Leo to visit and the timing is perfect if in fact he went to Ca.
http://www.ncbi.nlm.nih.gov/pubmed/?term=brilacidin
Mensa, Howell and DeGrado are at:
Department of Pharmaceutical Chemistry and the Cardiovascular Research Institute, University of California, San Francisco
Just the opposite if true. If this roundtable included the following,BARDA, NIH, FDA, grant agencies, pharma and academia, in the AMR discussion about animal feed then someone thought it more important than what was to be presented by Menon. Remember the AMR funding as part of the GAIN act has doubled to $1.2B and we want a piece of that pie.
Of all the industries across Canada, none could possibly be happier with Monday’s surprising election result than the medical marijuana sector, Peter Koven of Canada's Financial Post reports.
Justin Trudeau — who won in a landslide — has a plan to legalize marijuana promises to bring massive opportunity to an industry that only came into existence last year.
So was Menon involved in the Gov.GAIN act discussion?
This 2-day conference presents solutions through key notes, case study presentations, expert opinion, roundtable discussions and invites "KEY" influencers such as BARDA, NIH, FDA, grant agencies, pharma and academia, in the AMR discussion.
The World AntiMicrobial Resistance Congress gathers key stakeholders from government, funding agencies, pharma, academia and payers to discuss this urgent need for new antibiotics. President Obama has outlined his 5-year action plan to fight AMR and is seeking to double the AMR funding to $1.2B, but the bigger challenge is how to deliver these actions.
http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2013/11/07/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics
One of the GAIN Act's main provisions is Section 505E, which grants companies an additional five years of market exclusivity if they develop an antibiotic intended for a "qualified infectious disease." However, the act failed to describe which diseases are "qualified," leaving that distinction up to FDA regulators.
Those qualifying pathogens were as follows:Acinetobacter species Aspergillus species Burkholderia cepacia complex Campylobacter species Candida species Clostridium difficile EnterobacteriaceaeEnterococcus species Mycobacterium tuberculosis complexNeisseria gonorrhoeaeNeisseria meningitidisnon-tuberculous mycobacteria species Pseudomonas species.Staphylococcus aureus Streptococcus agalactiae Streptococcus pneumonia Streptococcus pyogenes Vibrio cholera Final Rule How ever, FDA has now released a final rule amending that list, adding several pathogens that were not in its draft form.
The three new qualifying pathogens are:Coccidioides species Cryptococcus species Helicobacter pylori
http://raps.org/regulatory-focus/news/2014/06/19395/FDA-Final-Rule-On-Qualifying-GAIN-Act-Pathogens/
I have looked on both days and could find nothing about animal feed discussions.
Perhaps it was added to the roundtable discussion at the end of day 2 by the NIH,FDA
15:10 Roundtable
http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/C57076.stm
INNOVATION. COLLABORATION.
COMMERCIALIZATION.
Our mission is to deliver an event that facilitates commercial solutions to the world’s most important health issue and promotes collaboration and novel technologies.
How can the GAIN Act be improved?
The GAIN act does include improved animal feed.
http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/our-story.stm
That's how Advaxis started out.
Animal and human cancers/infections are billion dollar industries, I doubt what you say is entirely true looking at the list of speakers.
I was hoping that a large pharmaceutical company approached him early, and when he gave them some interesting information they told him to call Leo with an offer they couldn't refuse.
Would be interesting if PMX 1502 or PMX 1408 were developed for Alzheimers.
BEVERLY, MA– Nov 18, 2013 – Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that it has made significant breakthroughs with its portfolio of novel drug candidates for infectious disease, including fungal infections and Gram-negative bacterium.
Oct 15 2015
"Different Brain Regions are Infected with Fungi in Alzheimer's Disease."
Collectively, our findings provide compelling evidence for the existence of fungal infection in the CNS from AD patients, but not in control individuals.
http://www.ncbi.nlm.nih.gov/pubmed/26468932
Has it been written that's what the dosing shall be?
That was done in phaseI possibly to build the drug up in the body.
Each patient will receive 3 weekly doses of Kevetrin given as a 1 hour intravenous infusion followed by a 1 week off-treatment period. Following each dose, each patient will be monitored. If the patients have acceptable safety and tolerance, Kevetrin will be given once weekly for a total of 3 weeks.
https://clinicaltrials.gov/ct2/show/NCT01664000
Yes it is a mouse study with a human leukemia cell line.
Not Kevetrin but close enough.
MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
MD Anderson
Oct.6, 2015
In summary, MDM2 inhibitor Nutlin 3a potently induces autophagy. While clinical development of several MDM2 inhibitors is in progress in cancer therapy, the biological impact of autophagy in their responses need to be explored.
Link
http://www.be-md.ncbi.nlm.nih.gov/pmc/articles/PMC4595506/
BMS should replace it's Paclitaxel with Kevetrin
Lung Cancer
Efficacy of Kevetrin or paclitaxel
in A549 drug resistant tumor
These results demonstrated that Kevetrin, but not paclitaxel, had potent anti-tumor activity against a
human lung adenocarcinoma xenograft tumor model, A549, at a dose and schedule that was welltolerated
as indicated by a small transient weight loss during treatment. These studies support the
development of Kevetrin in lung carcinoma indications, particularly in cases where tumors have become
resistant to standard chemotherapy.
Breast Cancer
Efficacy of Kevetrin, paclitaxel
in MDA-MB-435s tumor model
In this experiment, the growth of MDA-MB-435S human breast carcinoma tumors was significantly
delayed (p<0.01) following treatment with Kevetrin 68% compared to controls, whereas paclitaxel had
no efficacy in these tumors producing -6% tumor growth delay compared to controls. Tumor growth
delay with Kevetrin was also significantly greater than with paclitaxel (p<0.01). On measurements of
tumor volume at day 37, Kevetrin reduced tumor volumes by 83%, significantly more effective than
controls or paclitaxel (p<0.01).
An old read on what's next:
Cellceutix is preparing to file an IND for KM-391. As a small biotech with limited resources, however, Cellceutix has to concentrate on its leading compound. A successful IND and Phase I for Kevetrin will clear the path for KM-391. If KM-391 shows positive results in humans, it could completely change the way autism is treated. Like Kevetrin, this compound has multibillion-dollar potential.
As former director for the ALS foundation, Dr. Menon has considerable experience with neurological diseases. When he came across KM-391, originally developed in India, he saw its value and purchased the rights. He also improved the original compound.
Cellceutix has other candidates in its pipeline. It has preclinical and developmental-stage compounds for the treatment of psoriasis, arthritis, asthma, ALS, cancer and hypertension.
http://www.hotstockmarket.com/t/259020/ctix-cellceutix-corporation
Amgen has an updated patent for AMG900
And within this patent:
The invention also includes use of any other pre-clinical HDAC inhibitors, including without limitation, Kevetrin, an agent selective for HDAC2, that are later determined to be useful for the treatment of cancer via the reduction or inhibition of histone deacetylase activity in combination with AMG 900.
Interesting if they are studying Kevetrin
They do have a study with Vorinostat out.
CONCLUSIONS: These results indicate that AMG 900 may be a promising drug for the adjuvant treatment of MB (Medulloblastoma), mainly when combined with iHDAC.
http://www.ncbi.nlm.nih.gov/pubmed/26000978
I would say Andrea Bullock, one of the sub investigators of Kevetrin saw something unique.
On staff at Beth Israel Deaconess Medical CenterHarvard Medical Faculty Physicians (HMFP) at Beth Israel Deaconess Medical Center
Clinical Interest(s): Gastrointestinal Malignancy: Colorectal, Gastric, Neuroendocrine, and Pancreaticobiliary
Medical Oncology Andrea J. Bullock, MD Rebecca A. Miksad, MD Diane M.F. Savarese, MD Benjamin L. Schlecter, MD Neeharika Srivastava, MD
This is why there are so many sub investigators.
Maybe tomorrow when they come back from the holiday.
New SPORE grants for BIDMC Beth Israel Deaconess Medical Center
SPORE grant projects at MD Anderson
Specialized Programs of Research Excellence (SPORE) Grants (NCI)
Project 3
http://www.mdanderson.org/education-and-research/research-at-md-anderson/early-detection-and-treatment/research-programs/spores/multiple-myeloma-spore/research-projects/index.html
2013
Cellceutix inks MTA with MD Anderson for research of Kevetrin in lymphoma, multiple myeloma cancers
Search SPORE grants by state: Ma.& TX.
http://trp.cancer.gov/
Public Release: 28-Sep-2015
BIDMC receives $11.3M grant renewal for Kidney Cancer SPORE
In addition to McDermott and Mier, other BIDMC investigators on the SPORE grant include BIDMC Cancer Center researchers Rupal Bhatt, MD, PhD, Kathleen Mahoney, MD, and David Panka, PhD.
Mier is a sub-investigator on the Kevetrin trial
http://www.eurekalert.org/pub_releases/2015-09/bidm-br092815.php
Targeting the HDM-2 E3 Ligase in Multiple Myeloma
The ubiquitin-proteasome pathway has been validated as a therapeutic target for multiple myeloma (MM) by our group and others through the demonstration of the activity of bortezomib in both the relapsed/refractory and up-front settings. Because of its broad impact on intracellular proteolysis, however, this proteasome inhibitor induces anti-apoptotic effects at the molecular level that decrease its efficacy, and at the clinical level it induces toxicities. Therefore, the use of a more targeted approach, such as inhibiting a specific E3 ubiquitin ligase responsible for ubiquitination of only a small subset of client proteins, would likely be more effective and better tolerated.
We have obtained evidence that second-generation small molecule inhibitors of the HDM-2 E3 ligase, which is best known for its role in p53 ubiquitination, induce anti-proliferative effects in MM models irrespective of their p53 status; that these agents activate a p53-dependent type I cell death program, as well as p53-independent type II cell death, or autophagy; and that they interact synergistically with different classes of chemotherapeutics in wild-type and mutant p53 backgrounds. These and other findings led us to our central hypothesis that HDM-2 inhibitors are promising novel agents that can be used as chemosensitizers in a p53 status-adapted approach to personalize MM therapy and to individualize the therapy to the characteristics of each patient’s disease.
??
If we only had some drug patent that could compete with Daraprim (Pyrimethamine)that is all over the news.
Or do we?
Hybrid compounds and methods of making and using the same
WO 2014093231 A2
Anti-malarial compounds
US 20150072997 A1
The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the gr 5 owth of a Plasmodium species; inhibiting the growth of a Mycobacterium species
Ehrlich said that the one non-science employee besides himself only started answering the phone since the blog came out. “For a company our size, we don’t have a secretary. It’s not needed. ... I’d rather spend my money on research,” he said.
http://www.bizjournals.com/boston/blog/bioflash/2015/08/my-visit-to-cellceutix-the-biotech-that-a-short.html?ana=twt
My fellow shareholders,
Yesterday, we had a reporter from Boston Business Journal visit our facility. I would like to share with you his story.
http://www.bizjournals.com/boston/blog/bioflash/2015/08/my-visit-to-cellceutix-the-biotech-that-a-short.html?ana=twt
Newly identified mechanism of p53-induced cell death could aid cancer therapy
Researchers have identified a new mechanism that the tumor suppressor protein p53 uses to trigger cell death via apoptosis and have shown how the process could be harnessed to kill cancer cells. St. Jude Children's Research Hospital scientists led the study, which appears today in the scientific journal Molecular Cell.
http://medicalxpress.com/news/2015-07-newly-mechanism-p53-induced-cell-death.html
St. Jude is all over this.
Propanc Identifies Positive Signals for Efficacy from Pilot Animal Studies
For PRP, positive signals emerged from ovarian and two types of pancreatic cancers, where human derived cancer cells were injected into immune-compromised mice and grown over time, followed by treatment with PRP over a defined period. In ovarian cancer, a trend in the reduction of tumor weight, coupled with a reduction in the number of mice with distended (swollen due to pressure from inside) abdomens, most likely related to the size of the tumors, was notable. In two separate pancreatic cancer cell types, similar trends were observed with a reduction of tumor weight.
http://finance.yahoo.com/news/propanc-identifies-positive-signals-efficacy-120000385.html
"They haven’t made the connection to Beard
yet because none of them know about Beard, but Beard had
that whole theory 100 years ago. He went a step further and
said that, since the placenta is controlled by enzymes, cancer
will be controlled by enzymes because the cancer is really
placental cells growing in the wrong place at the wrong time."
"People thought that was just bizarre. Of course what
Beard had discovered—which no one realized, because no
one knew what they were—were stem cells."
Nicholas Gonzalez, MD: An Enzyme
Approach to Cancer
http://www.alternative-therapies.com/openaccess/ATHM_18-6_Gonzalez.pdf
Beard spent a number of years trying to figure out what
the signal was. Of course he realized the day the placenta
changed its character from this invasive, cancer-like tissue
into the mature noninvasive placenta was the day the embryonic
pancreas began pouring out pancreatic enzymes. In
1902, when Beard made that suggestion, pancreatic enzymes
had already been identified.
That has been confirmed 100 years later and he could
find no other correlation. He said since the placenta is virtually
like a tumor, and since pancreatic enzymes control placenta
differentiation and growth and maturation, pancreatic
enzymes must be the body’s main defense against cancer and
would be useful as a cancer treatment. Then he went from the
theoretic to the practical, used enzymes in an animal model,
and got a 100-percent regression of tumors using injectable
pancreatic enzymes that a drug company provided him. He
was not a physician, but physicians both in the United States
and Europe, under his direction, began using them in
advanced cancer patients and the tumors would regress.
HEADLINE: Pfizer (PFE) CEO Ian Read To Comment On Cellceutix Corporation (CTIX) Discussions This Week Ventures Sierra World Equity Review. Sierra is anticipating PFE will be releasing an official comment on the status of talks with CTIX possibly as early as Monday. Shares of CTIX finished marginally higher at the end of Friday's trading session. Look for the official news, when it breaks remember Sierra called this first!
With around one hundred production sites in 36 countries, Nestlé Waters has 33,500 employees and a portfolio of 63 unique brands
They would go directly to the source for this and Alpine Farms would be perfect for them, then they would grab Boreal for their 2 wells and aging bottling plant most likely for pennies on the dollar because without Alpine they wouldn't be much of a company.
There would be no lawsuit as Alpine has it in their contract, if Boreal cannot match the buyers price within 30 days of an acceptable offer then Alpine will sell it to the buyer. Please read the recent 10Q.
http://ih.advfn.com/p.php?pid=nmona&article=66842195
Note 11 – Commitments and Contingencies
Sounds like you don't understand that Boreal receives all it's NY spring water from Alpine Farms, now should someone decide to buy them and Boreal cannot match the offer within 30 days then there is no more spring water for them to tap.
Just too bad that they do not own the spring which is owned by Alpine Farms, someone can come in at any moment and make an offer for it.
The Company has an option of first refusal in the event that the owner enters into an agreement for the sale of all or a portion of the real property, which includes the springs located on the real property. Upon execution of a valid binding contract between the owner and a third party, which contract shall be made subject to the terms of the option, the owner shall provide the Company a copy of the contract and it shall have thirty (30) days from date of delivery or mailing within which to exercise its option by delivering to the owner a check in the amount of the contract deposit, in which event the owner and the Company shall be bound by the contract sale.
They should buy Alpine Farms and move the plant there, eliminating the trucking in of fresh water daily and saving boatloads of money.
Two sources of water here.
Water is transported from the springs 17 miles to Boreal’s bottling plant located 90 miles north of New York City in Kiamesha Lake and is passed through a series of multimedia particulate filters to remove any sediment.
- We bottle at the source- Natural spring water is drawn directly from our spring and bottled. There is no water transportation thus eliminating any possibility of contamination.
http://www.borealwater.com/boreal_water/boreal-water-production.php?var=production
Maybe Starbucks needs a partner?
May 08,2015
Starbucks pulls plug on Ethos water bottling in drought-stricken California
Seattle-based coffee chain will move operation to Pennsylvania
The Seattle-based coffee chain also is looking for a new source and supplier for its West Coast Ethos water distribution.
Differential Effects of Serine Proteases on the Migration of Normal and Tumor Cells: Implications for Tumor Microenvironment
Kirsten L. Elzer, Deborah A. Heitzman, Mitchell I. Chernin and Josef F. Novak
Integr Cancer Ther 2008; 7; 282
www.bucknell.edu/documents/biology/Novak-Elzer_et_al.pdf
The supporting role of proteases in tumor progression and
invasion is well known; however, the use of proteases as therapeutic agents has also been demonstrated. In this article, the authors report on the differential effects of exogenous serine
proteases on the motility of tumor and normal cells. The treatment
of normal and tumor cells with a single dose of pancreatic
serine proteases, trypsin (TR) and chymotrypsin (CH),
leads to a concentration-dependent response by cells, first
accelerating and then slowing mobility. Tumor cells are 10 to
20 times more sensitive to exogenous TR/CH, suggesting that
a single dose of proteases may cause discordant movements of
normal and tumor cells within the tumor environment.
From the Department of Pharmacology, Cornell University, Ithaca, New
York (KLE); Department of Biology, Bucknell University, Lewisburg,
Pennsylvania (DAH, MIC, JFN).
Was this site ever removed from the Brownfields list?
If not what is the estimated clean up cost?
Nevada Brownfields Projects — Site Profiles
Lambertucci-Roma ranch
http://ndep.nv.gov/bca/brownfield_lambertucci_roma.htm
This 605-acre site is located northwest of Tonopah at the Nye and Esmeralda County line. The site includes 100+ years of mixed development.
An asbestos survey needed to be done prior to any demolition, and any asbestos had to be disposed of safely. A small area of soil had been contaminated with petroleum products. Above and below ground storage tanks were found on this site; the former contents of these tanks must be characterized before safe disposal can take place. There are many 55-gallon drums throughout the site, none of which are labeled according to the former or current contents. Abandoned vehicles and vehicle parts have been found throughout the site, including engine blocks and fuel tanks. Apparent mine tailings were found both on and near the site. These tailings must be analyzed prior to disposal or re-development, as a characterization has not been done on common tailings in the Tonopah area.
There are several open mine shafts along with ore processing equipment, and some residual chemicals from ore processing may still be present. No remediation was completed, only a survey of the state of the site. Environmental liabilities outlined above currently exist on the site. Future development would need to characterize or remediate property further prior to unrestricted use.
It's all about protecting the cell signaling pathway.
Enhances E-cadherin & ß-catenin.
?
Decrease expression of EMT transcription factors responsible for cancer cell signalling pathways.
Enzyme news
http://www.nyas.org/Events/Detail.aspx?cid=60f29de3-d6c7-4b93-85b9-202968acd691
2015 Ross Prize in Molecular Medicine: Harnessing Cell Signaling Pathways to Treat Cancer
Phosphatidylinositol-4,5-bisphosphate 3-kinase (also called phosphatidylinositide 3-kinases, phosphatidylinositol-3-kinases, PI 3-kinases, PI(3)Ks, PI-3Ks or by the HUGO official stem symbol for the gene family, PI3K(s)) are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.
The man who dares to take on cancer (2013)
Human medicine and veterinary medicine may be entirely two different streams of science. But here is a man who has treaded the path of both the streams breaking the preconceived notion of treatingveterinary medicine and human medicine differently. Meet Dr E P Krishna Menon, a veterinary graduate-turned-oncologist and cancer research scientist who has developed nine cancer medicines and also owns four American pharmaceutical companies.
http://www.futuremedicineonline.com/detail_news.php?id=103
POSTERS ECCMID 2015
Poster O082
1-hour Oral Session
Drug discovery
Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections
The in vitro profile and PK data encouraged us to further
evaluate these leads for their efficacy against the Gram (-) pathogens, E.coli and K. pneumoniae in a mouse thigh burden model. At 24 h post infection, CC-1807 showed a superior reduction of bacterial burden (-5.21 log10 CFUs) than meropenem (-3.05 log10 CFUs) at dose 32 mg/kg and 25 mg/kg, respectively.
LINK
https://www.escmid.org/escmid_library/online_lecture_library/?search=1¤t_page=1&search_term=cellceutix
Poster EV0201
ePoster Viewing
Antimicrobials: new antimicrobials
Brilacidin, host defence peptide mimetic, one of a new class of immunomodulatory agents that can target multiple disease
indications
Conclusion
Oral ulcerative mucositis is a common, painful, dose-limiting toxicity of cancer therapy with minimal treatment options. The well-tolerated and efficacious HDP mimetic, brilacidin, in the animal model supports its further development as a topical therapeutic for OM. While we believe the efficacy in the OM model is primarily the result of brilacidin’s immunomodulatory activities, its antimicrobial function can also play a role in treating the lesions. Based on these promising studies, a Phase 2 trial in radiation induced OM is ongoing.